Posts

Posted on

Corsair Gaming to Present at B. Riley Securities 25th Annual Institutional Investor Conference

Corsair Gaming to Present at B. Riley Securities 25th Annual Institutional Investor Conference

MILPITAS, Calif.–(BUSINESS WIRE)–
Corsair Gaming, Inc. (Nasdaq: CRSR) (“Corsair” or the “Company”), a leading global provider and innovator of high-performance products for gamers, streamers, content-creators, and gaming PC builders, today announced it will attend to the B. Riley Securities 25th Annual Institutional Investor Conference on May 21, 2025, at the Ritz-Carlton in Marina Del Rey, California.

Michael G. Potter, Corsair’s Chief Financial Officer, will meet with institutional investors at the conference to discuss the Company’s recent financial results, business trends and growth opportunities.

About Corsair Gaming

Corsair (Nasdaq: CRSR) is a leading global developer and manufacturer of high-performance products and technology for gamers, content creators, and PC enthusiasts. From award-winning PC components and peripherals to premium streaming equipment and smart ambient lighting, Corsair delivers a full ecosystem of products that work together to enable everyone, from casual gamers to committed professionals, to perform at their very best. Corsair also sells products under its Fanatec brand, the leading end-to-end premium Sim Racing product line; Elgato brand, which provides premium studio equipment and accessories for content creators; SCUF Gaming brand, which builds custom-designed controllers for competitive gamers; Drop, the leading community-driven mechanical keyboard brand; and ORIGIN PC brand, a builder of custom gaming and workstation desktop PCs.

Investor Relations Contact:

David Pasquale

[email protected]

914-337-8801

Media Contact:

Timothy Biba

[email protected]

203-428-3222

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Electronic Games Internet Entertainment

MEDIA:

Logo
Logo
Posted on

Walker & Dunlop Arranges $22 Million Equity for Chicago Community

Walker & Dunlop Arranges $22 Million Equity for Chicago Community

BETHESDA, Md.–(BUSINESS WIRE)–Walker & Dunlop, Inc. is celebrating the ground breaking of Parkside 5, the fifth and final phase of the Parkside at Old Town development, a 99-unit community located on the former Cabrini-Green public housing site in Chicago’s Near North Side.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512455389/en/

Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)

Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)

The Walker & Dunlop affordable housing team, led by Jennifer Erixon, syndicated Low Income Housing Tax Credits (LIHTC) and Illinois Donation Tax Credits on behalf of the client, Holsten Real Estate Development Corporation. Walker & Dunlop Affordable Equity syndicated the equity to JP Morgan, resulting in $22.6 million of equity to support the development. In addition to syndicating the credits, JP Morgan is also providing a construction loan for the project.

The funding will support the construction of a mix of market-rate and affordable units, with 37 of the units benefiting from a 20-year Section 8 Housing Assistance Payment (HAP) contract. These affordable units will be reserved for households earning 50% and 60% of the area median income (AMI) or less. “We are proud to support the continued revitalization of the Near North Side, helping to bring much-needed affordable housing options to the community while contributing to the broader transformation of the former Cabrini-Green site,” said Jennifer Erixon, senior managing director of Affordable Equity Originations at Walker & Dunlop. “Our partners at Holsten have allowed us to provide a valuable solution that meets our shared goals.”

Parkside 5 will feature three 3-story walk-up buildings and an 8-story mid-rise structure with townhome units at its base. Planned amenities include a community room, fitness center, and onsite social services for residents. Additionally, a playground, and dog park, will be open to the community to position Parkside 5 as a vibrant, inclusive space for its residents and neighbors. The development will complement the existing phases of the Parkside at Old Town project, a key piece in the ongoing revitalization of the historic neighborhood.

Walker & Dunlop, the #2 multifamily finance lender in the US, has a long-standing commitment to affordable housing and continues to invest in its affordable platform to provide clients with unparalleled solutions for all of their needs. The team originated over $6.3 billion in affordable and workforce financing from 2021-2024 through HUD, Fannie Mae, Freddie Mac, and capital markets sources. To date, the platform has raised over $10 billion in LIHTC equity and sold more than 275 affordable properties across 40 states. To learn more about the team’s capabilities and financing options, visit our website.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States. Our ideas and capital create communities where people live, work, shop, and play. The diversity of our people, breadth of our brand and technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

Investors:

Kelsey Duffey

Investor Relations

Phone 301.202.3207

[email protected]

Media:

Nina H. von Waldegg

VP, Public Relations

Phone 301.564.3291

[email protected]

Phone 301.215.5500

7272 Wisconsin Avenue, Suite 1300

Bethesda, Maryland 20814

KEYWORDS: United States North America Illinois Maryland

INDUSTRY KEYWORDS: Communications Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Public Relations/Investor Relations

MEDIA:

Photo
Photo
Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)
Logo
Logo
Posted on

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

  • New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA
  • ‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patent
  • Does not impact FDA’s ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025

MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA™ (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dr. Roger Jeffs, CEO, Liquidia said: “We are not surprised by UTHR’s repeated, last-minute attempts to deny PAH and PH-ILD patients access to an alternative therapy. We have invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil in the past and will continue to defend the rights of patients suffering with these critical illnesses to choose the therapy that works best for them.”

The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB’s decision was affirmed by the U.S. Court of Appeals for the Federal Circuit in December 2023. The United States Supreme Court rejected UTHR’s petition for a writ of certiorari, thereby upholding PTAB’s decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.

UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Cautionary Statements Regarding Forward-Looking Statements 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware or the U.S. District Court for the Middle District of North Carolina, including rehearings or appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.   The invalidity of one patent is not necessarily determinative as to the validity of a second patent, even if the patents arise out of the same patent family or claim similar subject matter. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investors:

Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:

Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]



Posted on

KRISPY KREME® Celebrates PAC-MAN’s 45th Anniversary with A-maze-ing New Doughnut Collection

KRISPY KREME® Celebrates PAC-MAN’s 45th Anniversary with A-maze-ing New Doughnut Collection

Brand also challenges fans to “chomp” 45,000 FREE Original Glazed® Doughnuts May 12-18 and offers 25-cent Original Glazed® dozens on PAC-MAN Day May 22

CHARLOTTE, N.C.–(BUSINESS WIRE)–
Ready, players?! Krispy Kreme® today announced an a-maze-ing collaboration with Bandai Namco Entertainment America Inc., for PAC-MAN’s 45th Anniversary, celebrating the global, cultural icon with all-new doughnuts inspired by the classic game. Fans will want to chomp these new doughnuts before it’s “game over!”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512436944/en/

Brand also challenges fans to “chomp” 45,000 FREE Original Glazed® Doughnuts May 12-18 and offers 25-cent Original Glazed® dozens on PAC-MAN Day May 22

Brand also challenges fans to “chomp” 45,000 FREE Original Glazed® Doughnuts May 12-18 and offers 25-cent Original Glazed® dozens on PAC-MAN Day May 22

Available beginning today for a limited time at participating U.S. shops, the Krispy Kreme x PAC-MAN Collection features three new doughnuts in a nostalgic custom PAC-MAN game dozen box that’s the sweetest PAC-MAN level ever, including:

  • PAC-MAN Party Doughnut – an Original Glazed® Doughnut piped with yellow buttercreme flavored icing, sprinkled with celebration sprinkles and topped with a PAC-MAN piece.
  • TEAM GHOST Doughnut – an unglazed shell doughnut filled with chocolate flavored Kreme™, dipped in black icing, decorated with PAC-MAN maze and topped with Team Ghosts piece.
  • Strawberry Power Berry Doughnut – an unglazed shell doughnut filled with strawberry flavored Kreme™, dipped in red icing and topped with white sprinkles and green leaf icing.

PAC-MAN is one of the most recognized video game characters of all time and has made an impact on the world by connecting with people across ages, borders and genders through the power of play for over 45 years, just as Krispy Kreme connects people through the sweetness of enjoying and sharing doughnuts.

Krispy Kreme is also celebrating PAC-MAN’s 45th anniversary by:

  • Aiming to give guests 45,000 FREE Original Glazed® doughnuts between May 12 through 18 during Hot Light hours – 7 to 9 a.m. and 5 to 7 p.m., or whenever the Hot Light is shining – limit one per guest per day in shop and via drive-thru. In honor of PAC-MAN’s love of fruits, if fans help achieve this “high score,” they will unlock the return of Krispy Kreme’s popular Strawberry Glazed Doughnut, which the brand last offered for a limited time in August 2023.
  • Transforming its Doughnut Dots into “Pac-Dots” May 12 through 14, giving guests a FREE 10-count of Dots with the purchase of any dozen doughnuts at regular price.
  • Selling a dozen Original Glazed® doughnuts for just 25 cents with the purchase of any dozen at regular price on PAC-MAN Day, his official birthday, May 22.

“These all-new PAC-MAN doughnuts are sweetest in multi-player mode. So, press start on a dozen and chomp on a maze of flavors with family, friends and coworkers,” said Dave Skena, Krispy Kreme Chief Growth Officer. “Partnering with Bandai Namco and PAC-MAN is a new high score of sweetness.”

“This year marks an incredible milestone as we celebrate PAC-MAN’s legacy and his 45 years of impact,” said Karim Farghaly, senior vice president, business innovation and licensing at Bandai Namco Entertainment America Inc. “We are thrilled to partner with Krispy Kreme, another beloved iconic brand, to deliver a sweet experience for fans to enjoy just in time for PAC-MAN Day.”

The Krispy Kreme x PAC-MAN Collection is available in-shop and for pickup or delivery via Krispy Kreme’s app and website, individually and by the dozen. You can also enjoy the PAC-MAN doughnuts in a Krispy Kreme 6-pack box delivered fresh daily to select retailers. Visit krispykreme.com/locate/location-search#grocery to find a shop or retailer near you.

To learn more about the new Krispy Kreme x PAC-MAN Collection, visit krispykreme.com/promos/pac-man

Share how you’re celebrating PAC-MAN’s 45th Anniversary with the new Krispy Kreme x PAC-MAN Collection by using #KrispyKreme and tagging @krispykreme on social media and for PAC-MAN, by using #PACMAN45 and tagging @officialpacman on X and Instagram and @pacman on TikTok and Facebook.

About Krispy Kreme

Headquartered in Charlotte, N.C., Krispy Kreme is one of the most beloved and well-known sweet treat brands in the world. Our iconic Original Glazed® doughnut is universally recognized for its hot-off-the-line, melt-in-your-mouth experience. Krispy Kreme operates in 41 countries through its unique network of fresh doughnut shops, partnerships with leading retailers, and a rapidly growing digital business with more than 17,500 fresh points of access. Our purpose of touching and enhancing lives through the joy that is Krispy Kreme guides how we operate every day and is reflected in the love we have for our people, our communities, and the planet. Connect with Krispy Kreme Doughnuts at KrispyKreme.com and follow us on social: X, Instagram and Facebook.

About Bandai Namco Entertainment America Inc.

Bandai Namco Entertainment America Inc., part of the Bandai Namco Group, is a leading global publisher and developer of interactive entertainment for major video game consoles, PC, online, and mobile platforms. The company is known for creating many of the industry’s beloved classic franchises such as PAC-MAN®, GALAGA®, TEKKEN®, SOULCALIBUR®, and ACE COMBAT®, and publishing the critically acclaimed DARK SOULS™ series and the blockbuster title ELDEN RING™. Bandai Namco Entertainment America Inc. is also the premier publisher in the Western hemisphere for anime-based video games including GUNDAM™, NARUTO SHIPPUDEN™, DRAGON BALL™, and ONE PIECE®. Bandai Namco Entertainment America Inc. is headquartered in Irvine, California. More information about the company and its products can be found at http://www.bandainamcoent.com.

Category: Brand News

Liv Rockett

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Men Restaurant/Bar Entertainment Other Retail Family Specialty Consumer Food/Beverage General Entertainment Retail Other Consumer Women Electronic Games

MEDIA:

Photo
Photo
Brand also challenges fans to “chomp” 45,000 FREE Original Glazed® Doughnuts May 12-18 and offers 25-cent Original Glazed® dozens on PAC-MAN Day May 22
Photo
Photo
Brand also challenges fans to “chomp” 45,000 FREE Original Glazed® Doughnuts May 12-18 and offers 25-cent Original Glazed® dozens on PAC-MAN Day May 22
Logo
Logo
Posted on

NET Power, Inc. Class Action: The Gross Law Firm Reminds NET Power, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 17, 2025 – NPWR

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of NET Power, Inc. (NYSE: NPWR).

Shareholders who purchased shares of NPWR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/net-power-inc-loss-submission-form/?id=147727&from=4

CLASS PERIOD:
June 9, 2023 to March 7, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Net Power was unlikely to complete its first utility-scale plant, Project Permian, on schedule and the project was likely to be significantly more expensive than defendants had represented, because of, inter alia, supply chain issues and numerous site- and region-specific challenges; (ii) accordingly, defendants’ projections regarding the time and capital needed to complete Project Permian were unrealistic; (iii) the increased time and capital needed to complete Project Permian were likely to have a significant negative impact on the Company’s business and financial results; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

DEADLINE: June 17, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/net-power-inc-loss-submission-form/?id=147727&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NPWR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 17, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/net-power-inc-class-action-the-gross-law-firm-reminds-net-power-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-june-17-2025–npwr-302451608.html

SOURCE The Gross Law Firm

Posted on

Shareholders that lost money on Treace Medical Concepts, Inc.(TMCI) should contact The Gross Law Firm about pending Class Action – TMCI

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).

Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=147723&from=4

CLASS PERIOD:
May 8, 2023 to May 7, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the 3D bunion correction system, the “Lapiplasty”; (2) as a result, Treace Medical’s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: June 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=147723&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TMCI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-treace-medical-concepts-inctmci-should-contact-the-gross-law-firm-about-pending-class-action—tmci-302451610.html

SOURCE The Gross Law Firm

Posted on

Contact The Gross Law Firm by June 10, 2025 Deadline to Join Class Action Against BigBear.ai Holdings, Inc.(BBAI)

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of BigBear.ai Holdings, Inc. (NYSE: BBAI).

Shareholders who purchased shares of BBAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/bigbear-ai-holdings-inc-loss-submission-form/?id=147724&from=4

CLASS PERIOD:
March 31, 2022 to March 25, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) BigBear maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (ii) as a result, the Company incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under ASC 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (iii) accordingly, BigBear had improperly accounted for the 2026 Convertible Notes; (iv) the foregoing error caused BigBear to misstate various items in several of the Company’s previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; (vi) BigBear would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

DEADLINE: June 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bigbear-ai-holdings-inc-loss-submission-form/?id=147724&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BBAI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-the-gross-law-firm-by-june-10-2025-deadline-to-join-class-action-against-bigbearai-holdings-incbbai-302451596.html

SOURCE The Gross Law Firm

Posted on

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).

Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=147722&from=4

CLASS PERIOD: This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive. (b) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc. (c) sold shares of Cerevel stock contemporaneously with Bain Capital’s purchase of shares on or about October 16, 2023.

ALLEGATIONS: According to the complaint, Cerevel’s October 16, 2023 secondary stock offering (the “October Offering” or “Offering”) documents and other public statements omitted material facts regarding AbbVie’s interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel’s stock price until the merger was announced. Moreover, Cerevel’s controlling shareholder, Bain Capital Investors, LLC (“Bain”), acquired Cerevel shares from the October Offering at an artificially depressed price while allegedly in possession of material nonpublic information regarding AbbVie’s interest. On December 6, 2023, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share. The merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed Offering price. In addition, Cerevel’s January 18, 2024 Proxy statement misled investors regarding the true nature and timing of AbbVie’s interest in Cerevel.

DEADLINE: June 3, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=147722&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ABBV during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 3, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-cerevel-therapeutics-holdings-incabbv-shareholders-302451599.html

SOURCE The Gross Law Firm

Posted on

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Viatris Inc.(VTRS)

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).

Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=147721&from=4 

CLASS PERIOD:
August 8, 2024 to February 26, 2025

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning the failed inspection of Viatris’ Indore, India facility. Defendants’ statements misrepresented the FDA’s issuance of a warning letter and its impact on Viatris’ operations. Defendants routinely referred to the impact of the warning letter as a mere “minor headwind” for the Company.  On February 27, 2025, Viatris announced its financial results for the fourth quarter and full fiscal year 2024 and provided disappointing fiscal 2025 guidance. The Company attributed below-expectation guidance on “the expected financial impact from Indore facility warning letter and import alert.” Following this news, the price of Viatris’ common stock declined dramatically. From a closing market price of $11.24 per share on February 26, 2025, Viatris’ stock price fell to $9.53 per share on February 27, 2025, a decline of about 15.21% in the span of just a single day.

DEADLINE: June 3, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=147721&from=4 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of VTRS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 3, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-the-gross-law-firm-by-june-3-2025-deadline-to-join-class-action-against-viatris-incvtrs-302451600.html

SOURCE The Gross Law Firm

Posted on

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Open Lending Corporation(LPRO) Shareholders

PR Newswire


NEW YORK
, May 12, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Open Lending Corporation (NASDAQ: LPRO).

Shareholders who purchased shares of LPRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/open-lending-corporation-loss-submission-form/?id=147730&from=4

CLASS PERIOD:
February 24, 2022 to March 31, 2025

ALLEGATIONS: According to the filed complaint, defendants made false statements and/or concealed that they: (1) misrepresented the capabilities of the Company’s risk-based pricing models; (2) issued materially misleading statements regarding the Company’s profit share revenue; (3) failed to disclose the Company’s 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; and (4) misrepresented the underperformance of the Company’s 2023 and 2024 vintage loans. As a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: June 30, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/open-lending-corporation-loss-submission-form/?id=147730&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LPRO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 30, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-open-lending-corporationlpro-shareholders-302451601.html

SOURCE The Gross Law Firm